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Background: The optimal sequence of adjuvant chemotherapy and radiotherapy for breast cancer is
unknown. SECRAB assesses whether local control can be improved without increased toxicity.
Methods: SECRAB was a prospective, open-label, multi-centre, phase III trial comparing synchronous to
sequential chemo-radiotherapy, conducted in 48 UK centres. Patients with invasive, early stage breast
cancer were eligible. Randomisation (performed using random permuted block assignment) was strati-
fied by centre, axillary surgery, chemotherapy, and radiotherapy boost. Permitted chemotherapy regi-
mens included CMF and anthracycline-CMF. Synchronous radiotherapy was administered between
cycles two and three for CMF or five and six for anthracycline-CMF. Sequential radiotherapy was deliv-
ered on chemotherapy completion. Radiotherapy schedules included 40 Gy/15F over three weeks, and
50 Gy/25F over five weeks. The primary outcome was local recurrence at five and ten years, defined as
time to local recurrence, and analysed by intention to treat.
ClinicalTrials.gov NCT00003893.
Findings: Between 02-July-1998 and 25-March-2004, 2297 patients were recruited (1150 synchronous
and 1146 sequential). Baseline characteristics were balanced. With 10.2 years median follow-up, the
ten-year local recurrence rates were 4.6% and 7.1% in the synchronous and sequential arms respectively
(hazard ratio (HR) 0.62; 95% confidence interval (CI): 0.43–0.90; p = 0.012). In a planned sub-group
analysis of anthracycline-CMF, the ten-year local recurrence rates difference were 3.5% versus 6.7%
respectively (HR 0.48 95% CI: 0.26–0.88; p = 0.018). There was no significant difference in overall or
disease-free survival. 24% of patients on the synchronous arm suffered moderate/severe acute skin
reactions compared to 15% on the sequential arm (p < 0.0001). There were no significant differences in
late adverse effects apart from telangiectasia (p = 0.03).
Interpretation: Synchronous chemo-radiotherapy significantly improved local recurrence rates. This was
delivered with an acceptable increase in acute toxicity. The greatest benefit of synchronous chemo-
radiation was in patients treated with anthracycline-CMF.
Funding: Cancer Research UK (CR UK/98/001) and Pharmacia.
 2019 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology xxx (2019) xxx–xxx This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Standard of care when combining adjuvant treatment in opera-
ble early stage breast cancer is surgery with sequential chemother-apy (CT) followed by radiotherapy (RT) [1]. However, the optimal
integration of adjuvant treatment remains controversial [2–4].
Recht et al. (1996) randomised 244 patients after breast con-
serving surgery to receive radiotherapy before or after chemother-
apy [5]. Five year actuarial cancer recurrence rates suggested that
delaying chemotherapy until after radiotherapy may result in an
increased rate of distant metastases. Conversely the study showedy stage
2 SECRAB: A randomised, phase III, chemo-radiotherapy sequencing breast cancer trialthat delaying radiotherapy until after chemotherapy completion
leads to a higher risk of local recurrence (5% RT-CT versus 14% CT-
RT). These results suggested there may be an advantage in giving
synchronous chemo-radiotherapy as it would avoid delaying either
treatment and may shorten overall treatment duration, but risks
enhancement of both acute and late radiotherapy toxicities. How-
ever, in an update to the Recht et al., study, published after SECRAB
commenced, the initial differences observed were no longer statis-
tically significant between the chemotherapy-first and
radiotherapy-first arms after longer follow up (135 months) [6].
It is worthwhile noting that the addition of anthracycline
chemotherapy to adjuvant regimens was not routine practice in
the United Kingdom (UK) when SECRAB was conceived in the
mid-1990s. This subsequently became routine practice with a
moderate improvement in overall survival [7]. Care must be taken
when giving anthracyclines synchronously with radiotherapy due
to worsening of acute and late radiotherapy toxicity [8].
Three randomised controlled trials have subsequently investi-
gated synchronous versus sequential chemo-radiotherapy delivery
and demonstrate mixed results varying from no benefit to a signifi-
cantly improved five year loco-regional relapse free advantage in
axillary node positive patients [9–11]. All three studies utilised a five
week radiotherapy fractionation schedule. The ARCOSEIN trial ran-
domised 716 patients to receive chemotherapy followed by radio-
therapy or synchronous chemo-radiotherapy and showed a small
advantage innodepositivepatients infive-year loco-regional relapse
free survival in the synchronous arm (synchronous arm: 97% (7/154
recurrences); sequential arm: 91% (17/191 recurrences); p = 0.02)
[9]. The study byRouesse et al., also showed a borderline statistically
significant difference in local recurrence rates at five years (syn-
chronous arm: 3% (9/324 local recurrences); sequential arm: 7%
(20/314 local recurrences); p = 0.047) [10]. However in both these
studies there were significantly increased toxicities in the syn-
chronous arm both in acute skin reaction and late effects such as
fibrosis, breast shrinkage, telangiectasia, and oesophagitis. Limita-
tions in these studies included small numbers of patients recruited
andvariation in chemotherapy regimensutilised in each arm, partic-
ularly with the use of mitoxantrone which is no longer used in adju-
vant therapy due to the increased rate of leukaemia. The third study,
using CMF chemotherapy, recruited 206 patients and reported five
local recurrences in each arm [11]. Toxicity was not reported in the
initial publication but a later retrospective assessment reported a
four-fold increase in the odds of grade 2/3 fibrosis and breast retrac-
tion in the synchronous arm with no effect on telangiectasia [12].
There were mixed findings with regard to cosmesis [9,10,12].
The aims of the SECRAB trial were to establish whether syn-
chronous chemo-radiotherapy improves local recurrence and
whether this can be delivered with acceptable toxicity.Methods
Study design
This pragmatic randomised controlled, open-label phase III trial
was conducted in 48 centres in the UK and patients were recruited
by 63 consultants. The protocol and subsequent amendments were
approved by theWest Midlands Multi-centre Research Ethics Com-
mittee and by the research and development department at each
centre. The current version of the protocol can be found here:
www.birmingham.ac.uk/secrab Oversight of the trial was provided
by an independent Data Monitoring Committee.Patients
Patients with histological confirmed, invasive, early stage breast
cancer with no evidence of metastatic disease were eligible for thisPlease cite this article as: I. N. Fernando, S. J. Bowden, K. Herring et al., Synchr
breast cancer (SECRAB): A randomised, phase III, trial, Radiotherapy and Oncostudy. Patients were required to have complete macroscopic exci-
sion of their tumour by mastectomy or breast conserving surgery.
Additional eligibility criteria included; clear indication for adjuvant
chemotherapy and radiotherapy, with adequate medical fitness
including preserved cardiac, renal, hepatic and bone marrow func-
tion, and provision of written informed consent. Exclusion criteria
included; prior chemotherapy, previous cancer, and pregnancy. No
patients in the mastectomy group had immediate reconstruction
however delayed reconstruction was allowed depending on
patient and clinician choice.Randomisation and masking
Following informed consent eligible patients were randomised
(1:1) to sequential treatment, chemotherapy followed by radio-
therapy (control arm) or synchronous treatment, radiotherapy
given concurrently or as a sandwich with chemotherapy (research
arm). Randomisation was performed centrally by the Cancer
Research UK Clinical Trials Unit (CRCTU) at the University of Birm-
ingham using a computer generated random permuted block
assignment. Stratification was performed according to centre, axil-
lary surgery, chemotherapy regimen and inclusion of radiotherapy
boost. Patients were also given the option of participating in qual-
ity of life, dose intensity and cosmesis sub-studies.Procedures
Patients were treated with adjuvant chemotherapy from proto-
col mandated regimens reflective of common practice at the time
of recruitment. Permitted regimes were cyclophosphamide,
methotrexate and 5-fluorouracil + folinic acid (CMF; intravenous
or oral; six cycles), four cycles of anthracycline followed by four
cycles of CMF, or Mitomycin-C, Mitoxantrone and Methotrexate
(MMM). Approved chemotherapy schedules are listed in Table 1.
Radiotherapy practice was not standardised in the UK when this
trial was running. However the Standardisation of Radiotherapy
(START) trial was run in parallel to SECRAB [13]. Therefore, in those
centres running both SECRAB and START Quality Assurance (QA)
was applied as per START to the radiotherapy treatments during
SECRAB. Those centres not recruiting to START had their own in-
house QA protocol which was mandatory in the UK as part of the
Quality of Assurance in Radiotherapy (QUART) guidance which
came into place in 1993. Six widely used standard radiotherapy
schedules were permitted ranging from 15 to 25 daily fractions
(see table 1) with or without subsequent boost doses. Radiother-
apy was allowed to the breast or chest wall, the axilla and supra-
clavicular fossa at the clinicians’ discretion. Both 2D, and 3D
planning (once available), were permitted. Internal mammary
node irradiation was not allowed. It was advised that patients with
excessively large breast size should be excluded as they might be
at greater risk of acute skin toxicity [14]. The recommended regime
for synchronous therapy was 40 Gy in 15 fractions with optional
boost, but other doses were allowed including 45 Gy in 20 fractions
and 50 Gy in 25 fractions. When radiotherapy courses >3 weeks
were given synchronously, radiotherapy was omitted on the day
of chemotherapy administration. In anthracycline containing regi-
mens, synchronous radiotherapy was given after the intravenous
component of the first cycle of CMF, once anthracycline was com-
pleted. In CMF/MMM regimens the synchronous radiotherapy was
delivered after the intravenous component of the second or third
cycle of chemotherapy. For patients having a radiotherapy boost
the subsequent CMF/MMM chemotherapy could be deferred by
one week for patients treated in the synchronous arm. Hormone
therapy was allowed at clinicians’ discretion. Patients were fol-
lowed up annually for ten-years.onous versus sequential chemo-radiotherapy in patients with early stage
logy, https://doi.org/10.1016/j.radonc.2019.10.014
Table 1
Chemotherapy regimens and radiotherapy schedules.
Chemotherapy
regimens
Dose
(mg/
m2)
Route Frequency Cycle
duration
(days)
Number
of cycles
CMF Regimens
CMF ‘‘Classical”
Cyclophosphamide 100 Oral D114 28 6
Methotrexate 40 IV D1+8
5-Fluorouracil 600 IV D1+8
+ Folinic acid: 15 mg oral 4 hourly  6 doses 24 hours after methotrexate
CMF ‘‘Classical” IV
Cyclophosphamide 600 IV D1+8 28 6
Methotrexate 40 IV D1+8
5-Fluorouracil 600 IV D1+8
+ Folinic acid: 15 mg oral 4 hourly  6 doses 24 hours after methotrexate
CMF (6–8) IV 3-Weekly (Scottish Breast Group Schedule)
Cyclophosphamide 750 IV D1 21 6–8
Methotrexate 50 IV D1
5-Fluorouracil 600 IV D1
Anthracycline-containing Regimens
3-Weekly Epirubicin/CMF (Scottish Breast Group Schedule)
Epirubicin 100 IV D1 21 4
Followed CMF (6–8) IV 3-Weekly (Scottish Breast Group Schedule) for 4 cycles
Epirubicin + ‘‘Classical” CMF
Epirubicin, or
Doxorubicin
100
75
IV
IV
D1 21 4
Followed by CMF ‘‘Classical” oral or IV for 4 cycles
Bonadonna Regimen
Adriamycin 75 IV D1 21 4
Followed IV 3-Weekly CMF for 4–8 cycles
Mitomycin-C, Mitoxantrone and Methotrexate
Mitoxantrone 8 IV D1 21 6
Methotrexate 35 IV D1
Mitocycin-C 8 IV D1
+ Folinic acid: 15 mg oral 4 hourly  6 doses 24 hours after methotrexate
Radiotherapy
Schedules
Dose (Gy) Number of
fractions
Duration
(weeks)
39 13 5
40 15 3
42.5 (chest wall only,
no boost)
15 3
45 20 4
46 23 4 ½
50 25 5
IV = intravenous; D = day
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The primary outcome measure defined in the protocol was local
recurrence rates at five and ten years. Local recurrence was not
defined in the protocol hence local recurrence (ipsilateral breast/
chest wall only) defined as the time from randomisation to the ear-
liest documentation of recurrence is reported as the primary out-
come measure. In addition, loco-regional in-field recurrences
(ipsilateral breast/chest wall, axilla and/or supraclavicular fossa)
is also reported. The first site of recurrence was recorded for anal-
ysis but simultaneous or later loco-regional recurrences were
noted. Secondary outcome measures in all patients were distant
recurrence rates, survival (disease free survival and overall sur-
vival), along with acute toxicity causing significant treatment delay
or dose reduction, and other late effects of treatment.
Radiotherapy-induced acute skin toxicity was graded according
to the scoring system described previously by Fernando et al., as
none, mild (mild/moderate erythema; no dry or moist desquama-
tion), moderate (marked erythema, 5–10% dry of moist desquama-
tion with complete healing within four weeks), or severe (dry or
moist desquamation in >10% or skin reaction causing delay orPlease cite this article as: I. N. Fernando, S. J. Bowden, K. Herring et al., Synchr
breast cancer (SECRAB): A randomised, phase III, trial, Radiotherapy and Oncoincomplete healing or ulceration >4 weeks post-radiotherapy)
[14]. This system shows simplified equivalence to the toxicity cri-
teria of the Radiation Therapy Oncology Group (RTOG) in which
moderate skin reaction would be completely healed within four
weeks and severe skin toxicity would not be healed by four weeks
[15]. At the time of trial initiation, lymphedema was not part of any
late-effect scoring system, therefore we developed our own scoring
system according to a protocol equivalent to the European Organ-
isation for Research and Treatment of Cancer (EORTC) toxicity scale
and National Cancer Institute (NCI) Common Toxicity Criteria (CTC)
grading system with nil/mild being none or asymptomatic requir-
ing no treatment, moderate being requiring treatment but reversi-
ble and severe being non-reversible and/or affecting limb function.
This was analogous to grades 0/1, 2 and 3 later published by
Burmeister et al. [16]. Telangiectasia was graded as minimal, mod-
erate, or severe as previously described by Turesson and Thomas
[17]. Other adverse reactions to radiotherapy were recorded as
present or absent. All serious adverse events (SAEs) were recorded.
Outcome measures in the detailed sub-study included; reduc-
tion in dose intensity of chemotherapy, cosmetic result and quality
of life. Changes in breast appearance (photographic) were scored
by three observers blind to patient identity, treatment allocation,
and year of follow-up, and a final agreed score reached by consen-
sus as per the START trial [18]. Quality of life was measured using
the EORTC QLQ-C30 (version 2) core questionnaire, the EORTC-QLQ
BR23 (version 1) supplementary Breast Cancer module (BR23), and
the Women’s Health Questionnaire completed at baseline, on com-
pletion of chemo-radiotherapy, one, two, and five years following
surgery.Statistical analysis
At study conception local recurrence rates were reported to be
5–10% [19]. Thus recruiting 2000 patients would detect a 4% differ-
ence with 80% power and 3% difference with 65% power at a 5%
level of significance. To provide sufficient statistical power to per-
form the sub-group analyses, 1000 patients receiving each of the
two principal chemotherapy regimens (CMF and anthracycline-
CMF) were recruited into the study allowing detection of a 5% dif-
ference in local recurrence rates, with 80% power and a 5% level of
significance. The chemotherapy regimen was chosen prior to ran-
domisation and was also a stratification factor to ensure an equal
distribution to each arm. Analyses were performed on the ‘inten-
tion to treat’ population which included all patients as randomised
who provided consent. Differences in time to event outcomes
between treatment arms were summarised using Kaplan-Meier
plots and quantified as hazard ratios (HRs) with 95%-confidence
intervals (CIs) along with P-values estimated using Cox
proportional-hazards model with and without adjustments for
stratification factors. The primary analysis (time to local recur-
rence) and time to loco-regional in-field recurrence are estimated
using Cox proportional-hazards model and presented without
adjustment for stratification factors. The sub-group analyses for
anthracycline-CMF and CMF (local recurrence), distant recurrence,
disease free survival and overall survival have all been estimated
using Cox proportional-hazards model and presented with adjust-
ment for stratification factors. Unplanned sub-group analyses were
performed and Hazard Ratios (HRs) estimated via Cox
proportional-hazards model with adjustment for stratification fac-
tors, and presented in a forest plot for patient and disease charac-
teristics, and for treatment factors. Heterogeneity has been
assessed using the I2 statistic. Chi-squared tests were used to com-
pare the number of patients with moderate/severe toxicity versus
none/mild across both treatment arms and patients who have and
have not experiences a specific toxicity. In addition, a plannedonous versus sequential chemo-radiotherapy in patients with early stage
logy, https://doi.org/10.1016/j.radonc.2019.10.014
4 SECRAB: A randomised, phase III, chemo-radiotherapy sequencing breast cancer trialcomparison of toxicity between the treatment arms was adjusted
for radiotherapy schedule (three weeks versus > 3 weeks).
Analyses were performed using Stata 15.1.Role of the funding source
Funding for SECRAB was provided by Cancer Research UK. A
small educational grant was provided by Pharmacia for collection
of photographs. The funders of the study had no role in study
design, data collection, data analysis, data interpretation, or writ-
ing of the report. The corresponding author had full access to all
the data in the study. The corresponding author had final respon-
sibility for the decision to submit for publication.
Results
Between 02-July-1998 and 25-March-2004, 2297 patients were
recruited into the trial, 1150 were assigned to the synchronous arm
and 1146 to the sequential arm (Fig. 1). One patient was subse-
quently found to have not provided full informed consent and
was excluded. Baseline characteristics were evenly balanced
between the two arms (Table 2). The majority of patients were
node positive (1422/2296, 61.9%) with 538 (23.4%) of 2296
patients having more than four involved axillary lymph nodes
and 1312 (57.1%) patients having grade 3 disease.
A larger proportion of patients received CMF (1244/2296, 54.2%)
chemotherapy than anthracycline containing treatment
(1041/2296, 45.3%). Of the patients receiving anthracycline con-
taining regimens, 1011 received epirubicin-CMF, with 30 patients
receiving either a Bonadonna regimen of Adriamycin-CMF or a vari-Fig. 1. SECRAB trial profile. The following patients did not receive allocated intervention
CT not given n = 0, RT not given n = 17. Discontinued intervention refers to participants
n = 79, withdrawn from RT n = 7; sequential therapy – withdrawn from CT n = 82, with
therapy – n = 8; sequential therapy – n = 6).
Please cite this article as: I. N. Fernando, S. J. Bowden, K. Herring et al., Synchr
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not receive chemotherapy. A total of 2258 (98.3%) of 2296 patients
received radiotherapy. Themajority of patients received 40 Gy in 15
fractions over three weeks (1392/2296, 60.6%) or 42.5Gy in 15 frac-
tions over three weeks with no boost (343/2296, 14.9%), with the
remainder receiving schedules >3 weeks (523/2296, 22.8%). The
treatment delivered was balanced between the arms, including
patients receiving radiotherapy boost (Table 3).
With a median follow-up of 10.2 years (IQR: 9.7, 10.5), local
relapses were observed in 45 (3.9%) of the 1150 patients ran-
domised to synchronous therapy and 72 (6.3%) of 1146 patients
assigned to sequential therapy (Table 4). The five-year local recur-
rence rate was 2.7% (95% CI: 1.9–3.9) in synchronous arm and 5.1%
(95% CI: 3.9–6.6) in the sequential arm, similar results were seen
for the loco-regional in-field recurrence rates (Table 4). Ten-year
local recurrence rates were 4.6% and 7.1% in the synchronous and
sequential arms respectively, with a significant benefit of syn-
chronous treatment, with a HR of 0.62 (95% CI: 0.43–0.90;
p = 0.012) (Fig. 2A), and also loco-regional in-field recurrences,
with a HR of 0.63 (95% CI: 0.44–0.91; p = 0.014) (Fig. 2B). These
results are consistent with the adjusted results. Table 4 also sum-
marises the distribution of cases depending on whether they first
recurred locally, regionally or both together. Six case (two in the
synchronous arm and four in the sequential) occurred in both
the breast/chest wall and regional lymph nodes at the same time.
A forest plot of local recurrence according to sub-groups is pre-
sented in Fig. 3. Although no evidence of heterogeneity was
observed, the results indicate a trend towards benefit of syn-
chronous chemo-radiotherapy throughout, other than for grade 1
tumours (which included only three events).: synchronous therapy – CT not given n = 2, RT not given n = 6; sequential therapy –
who discontinued the trial treatment (synchronous therapy – withdrawn from CT
drawn from RT n = 5) or were lost to follow-up while on treatment (synchronous
onous versus sequential chemo-radiotherapy in patients with early stage
logy, https://doi.org/10.1016/j.radonc.2019.10.014
Table 2
Patient characteristics.
Synchronous Sequential Total
N = 1150 N = 1146 N = 2296
Patient baseline characteristics, n (%)
Age (years)
Median 52 51 51
Interquartile range 45–58 45–58 45 – 58
Range 24–77 24–79 24 – 79
<50 481 (41.8) 493 (43.0) 974 (42.4)
50 669 (58.2) 653 (57.0) 1322 (57.6)
Type of Surgery
Mastectomy 514 (44.7) 497 (43.4) 1011 (44.0)
Wide Local Excision 625 (54.3) 643 (56.1) 1268 (55.2)
Other 11 (1.0) 6 (0.5) 17 (0.8)
Vascular/Lymphatic Invasion
Not seen 624 (54.2) 621 (54.2) 1245 (54.2)
Present 523 (45.5) 521 (45.5) 1044 (45.5)
Unknown 3 (0.3) 4 (0.3) 7 (0.3)
Number of Nodes
Negative 428 (37.2) 444 (38.7) 872 (38.0)
1–3 positive 444 (38.6) 440 (38.4) 884 (38.5)
4 + positive 277 (24.1) 261 (22.8) 538 (23.4)
Missing 1 (0.1) 1 (0.1) 2 (0.1)
Tumour Grade
Grade 1 – Well differentiated 76 (6.6) 68 (5.9) 144 (6.3)
Grade 2 – Moderately differentiated 415 (36.1) 411 (35.9) 826 (36.0)
Grade 3 – Poorly differentiated 654 (56.9) 658 (57.4) 1312 (57.1)
Unknown 5 (0.4) 9 (0.8) 14 (0.6)
Tumour Size (mm)
N 1136 1137 2273
Median 22 22 22
Interquartile range 16–30 16–30 16–30
Range 2–100 2–210 2–210
ER Status
Negative 401 (34.9) 387 (33.8) 788 (34.3)
Positive 703 (61.1) 724 (63.2) 1427 (62.2)
Unknown 46 (4.0) 35 (3.0) 81 (3.5)
PgR Status
Negative 250 (21.7) 255 (22.5) 505 (22.0)
Positive 265 (23.1) 258 (22.7) 523 (22.8)
Unknown 635 (55.2) 623 (54.8) 1268 (55.2)
HER2 Status
Negative 104 (9.0) 122 (10.7) 226 (9.9)
Positive 39 (3.4) 44 (3.8) 83 (3.6)
Unknown 1007 (87.6) 980 (85.5) 1987 (86.5)
Present Menopausal Status
Pre 400 (34.8) 408 (35.6) 808 (35.2)
Peri 91 (7.9) 95 (8.3) 186 (8.1)
Post 524 (45.6) 515 (44.9) 1039 (45.2)
Unknown 135 (11.7) 128 (11.2) 263 (11.5)
Endocrine Therapy
Ovarian ablation
No 1077 (93.6) 1063 (92.8) 2140 (93.2)
Yes 64 (5.6) 75 (6.5) 139 (6.1)
Unknown 9 (0.8) 8 (0.7) 17 (0.7)
Tamoxifen
No 363 (31.6) 353 (30.8) 716 (31.2)
Yes, with CT 319 (27.7) 295 (25.7) 614 (26.7)
Yes, after CT 454 (39.5) 490 (42.8) 944 (41.1)
Unknown 14 (1.2) 8 (0.7) 22 (1.0)
Other Hormone Manipulation
No 1116 (97.0) 1121 (97.8) 2237 (97.4)
Yes 24 (2.1) 15 (1.3) 39 (1.7)
Unknown 10 (0.9) 10 (0.9) 20 (0.9)
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the ten-year local relapse rates for synchronous and sequential
patients were 3.5% versus 6.7% respectively, with a HR 0.48 (95%
CI: 0.26–0.88; p = 0.018). While for CMF, the ten-year local relapse
rates of 5.6% versus 7.5% for synchronous and sequential patientsPlease cite this article as: I. N. Fernando, S. J. Bowden, K. Herring et al., Synchr
breast cancer (SECRAB): A randomised, phase III, trial, Radiotherapy and Oncorespectively were observed, which was not significant (HR 0.70
(95% CI: 0.44–1.13; p = 0.149)).
The ten-year distant recurrence rate of 25.5% in the syn-
chronous arm versus 24.6% in the sequential arm with an HR of
1.04 (95% CI: 0.88–1.22; p = 0.68). Disease free survival and overallonous versus sequential chemo-radiotherapy in patients with early stage
logy, https://doi.org/10.1016/j.radonc.2019.10.014
Table 3
Treatments delivered.
Synchronous Sequential Total
N = 1150 N = 1146 N = 2296
Treatment delivered
Chemotherapy+
CMF 617 (53.7) 627 (54.7) 1244
(54.2)
Anthracycline-CMF 525 (45.7) 516 (45.0) 1041
(45.3)
Other 6 (0.5) 3 (0.3) 9 (0.4)
Not given 2 (0.2) 0 (0.0) 2 (0.1)
Radiotherapy+
39 Gy in 13 fractions over 5 weeks 10 (0.9) 8 (0.7) 18 (0.8)
40 Gy in 15 fractions over 3 weeks 706 (61.4) 686 (59.9) 1392
(60.6)
42.5Gy in 15 fractions, 3 weeks, no
boost
174 (15.1) 169 (14.7) 343 (14.9)
45 Gy in 20 fractions over 4 weeks 73 (6.3) 68 (5.9) 141 (6.1)
46 Gy in 23 fractions over 4 ½
weeks
69 (6.0) 76 (6.6) 145 (6.3)
50 Gy in 25 fractions over 5 weeks 108 (9.4) 111 (9.7) 219(9.5)
Radiotherapy not given 6 (0.5) 23 (2.0) 29 (1.3%)
Missing 4 (0.3) 5 (0.4) 9 (0.4)
Boost Given+
No 803 (69.8) 762 (66.5) 1565
(68.2)
Yes 340 (29.6) 360 (31.4) 700 (30.5)
Radiotherapy not given 6 (0.5) 23 (2.0) 29 (1.3%)
Missing 1 (0.1) 1 (0.1) 2 (0.1)
Time from Surgery to Radiotherapy, weeks (interquartile range)
CMF 12 (10–15) 30 (27–
33)
21.5 (12–
30)
Anthracycline + CMF 19 (18–21) 34 (31–
36)
26 (19–
34)
MMM 11.5 (10–12) 27 (25–
38)
12 (11–
25)
+ This table shows the treatment actually received instead of treatment intent.
Table 4
Local recurrence rates based on first site of occurrence.
Synchronous Sequential
N = 1150 N = 1146
Local Recurrence Rates, % (CI) p-value
Local recurrence 0.012
5-year 2.7 (1.9-3.9) 5.1 (3.9–
6.6)
10-year 4.6 (3.5-6.2) 7.1 (5.7–
8.9)
Loco-regional in-field recurrence 0.014
5-year 2.8 (2.0-4.0) 5.2 (4.0–
6.7)
10-year 4.8 (3.6-6.4) 7.3 (5.8–
9.1)
Local and Regional In-field Recurrences, n Total
Local recurrence alone 42 (3.7) 64 (5.6) 106 (4.6)
Local recurrence with a regional in-
field recurrence
2 (0.2) 4 (0.3) 6 (0.3)
Regional in-field recurrence without
a local recurrence
3 (0.3) 6 (0.5) 9 (0.4)
Loco-regional in-field recurrences 47 (4.1) 74 (6.5) 121 (5.3)
P values were calculated by the Cox proportional-hazards model.
Fig. 2. Kaplan–Meier 10-year analyses of primary outcome measures. Panel A
shows the primary outcome of local tumour recurrence rates, defined as the time
from randomisation to the earliest documentation of local recurrence. Panel B
shows the primary outcome of loco-regional in-field recurrence rates, defined as the
time from randomisation to the earliest documentation of loco-regional in-field
recurrence. Patients were censored at date of death or date last seen. The Kaplan-
Meier function (1-survival time) has been plotted for the above panels. The
unadjusted hazard ratios, 95% confidence intervals and p-values were derived from
Cox regression models. CI = Confidence Interval.
6 SECRAB: A randomised, phase III, chemo-radiotherapy sequencing breast cancer trialsurvival were not statistically different between the two arms. The
ten-year disease free survival rate was 64.9% in the synchronous
arm (404 recurrences) and 64.6% in the sequential arm (406 recur-
rences) with HR 1.00 (95% CI: 0.87–1.14; p = 0.951) (Fig. 4A). The
ten-year overall survival rate was 72.4% in the synchronous arm
with a total of 316 deaths from any cause and 73.4% in the sequen-
tial arm with 312 deaths; HR 1.02 (95% CI: 0.87–1.19; p = 0.824)Please cite this article as: I. N. Fernando, S. J. Bowden, K. Herring et al., Synchr
breast cancer (SECRAB): A randomised, phase III, trial, Radiotherapy and Onco(Fig. 4B). In an unplanned exploratory sub-group analysis for
patients receiving anthracycline-CMF the ten-year disease free sur-
vival rate was 67.7% in the synchronous arm compared to 63.5% in
the sequential arm (HR = 0.86 (95% CI: 0.70–1.06; p = 0.170)). Fur-
thermore, the overall survival rate for this unplanned exploratory
sub-group analysis was 75.8% in the synchronous arm compared
to 72.3% in the sequential arm (HR = 0.85 (95% CI: 0.66–1.08;
p = 0.171)).
Of those patients who received any modification to their treat-
ment plan, 626 were due to chemotherapy-related toxicities. The
most common reasons were myelosuppression (140 (12.2%) in
the synchronous arm, 98 (8.6%) in the sequential (p = 0.004)), oral
gastrointestinal toxicities (66 (5.7%) in the synchronous arm, 78
(6.8%) in the sequential (p = 0.297)) and infection (61 (5.3%) in
the synchronous arm, 57 (5.0%) in the sequential (p = 0.713)). Of
those patient whose radiotherapy delays were >7 days, more were
observed in the synchronous arm compared to the sequential arm
(1.0% (n = 12) versus 0.3% (n = 3); p = 0.02). Only two of which were
attributed to neutropenia, both occurring in the synchronous arm.onous versus sequential chemo-radiotherapy in patients with early stage
logy, https://doi.org/10.1016/j.radonc.2019.10.014
Fig. 3. Forest plot of local recurrence according to sub-groups. The solid vertical line represents the null hazard ratio value of 1. Horizontal lines represent confidence intervals
with hazard ratios indicated by diamonds. Conservative surgery includes wide local excision and quadrantectomy. RT schedules are based on treatment intent at
randomisation. Chemotherapy regimen is based on treatment intent at randomisation and it is presented this way as it is powered for in the study. + shows stratification
variables. Chemotherapy regimen, radiotherapy schedule and radiotherapy boost were based on intent to treat not actual treatment given. * 3 weeks includes the following
radiotherapy schedules: 40 Gy in 15 fractions delivered over 3 weeks and 42.5 Gy in 15 fractions delivered over 3 weeks; >3 weeks includes the following radiotherapy
schedules: 39 Gy in 13 fractions delivered over 5 weeks, 46 Gy in 23 fractions delivered over 4 ½ weeks, 45 Gy in 20 fractions delivered over 4 weeks and 50 Gy in 25 fractions
delivered over 5 weeks. CI = Confidence Interval.
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relevance.
Although differences in the synchronous arm were observed,
importantly, there was no significant difference in dose reduction
of >20% between the synchronous and sequential arms. This was
confirmed in the detailed dose intensity sub-study analysis; 372
(88.4%) of 421 patients in the synchronous arm received >85% dose
intensity of chemotherapy, compared to 369 (90.0%) of 410 of
patients in the sequential arm [20].
Acute skin toxicity was more common with synchronous radio-
therapy; 275 (24.0%) patients developed either a moderate or sev-
ere acute skin reaction with synchronous treatment compared to
166 (14.8%) for those treated with sequential therapy
(p < 0.0001). Of these, 44 (3.8%) patients had a severe reaction in
the synchronous arm compared to 12 (1.1%) treated sequentially.
However an unplanned exploratory analysis by radiotherapy
schedule showed that patients receiving >3 weeks of radiotherapy
had a significantly worse acute skin reaction than those receiving
three weeks (24.5% versus 16.7%; p < 0.0001). There was an
increase in moderate/severe telangiectasia of the treated area in
the synchronous arm compared to the sequential arm (35/1150
(3.0%) versus 19/1146 (1.7%), respectively; p = 0.03). No statistical
difference in telangiectasia was seen in those patients treatedPlease cite this article as: I. N. Fernando, S. J. Bowden, K. Herring et al., Synchr
breast cancer (SECRAB): A randomised, phase III, trial, Radiotherapy and Oncousing a three-weekly schedule comparing synchronous to sequen-
tial (19/782 (2.4%) versus 9/774 (1.2%), respectively; p = 0.06).
No evidence of a difference was observed in any other effects
including lymphedema, subcutaneous fibrosis, rib fracture, symp-
tomatic acute and late pneumonitis, ischaemic heart disease,
breast shrinkage, or brachial plexopathy (table 5). Detailed patient
reported outcomes including cosmesis and global quality of life
showed no difference over a five-year period [21,22].
There were 255 Serious Adverse Events (SAEs) reported in the
trial, 123 on the synchronous and 132 on the sequential arm.
Myelosuppression and subsequent neutropenic sepsis were the
most common SAEs related to chemotherapy, noted in 117/2296
(5.1%) patients. Of these, 62 patients received synchronous treat-
ment and 55 patients received sequential treatment. An SAE was
reported for one patient, on the sequential arm who received
CMF, who developed myelodysplasia approximately two years
after the completion of radiotherapy. This progressed to Acute
Myeloid Leukaemia from which the patient subsequently died.
Thirteen SAEs were reported as related to radiotherapy, of
which seven events (six patients) were regarded, on review by
the Chief Investigator, as being related to the radiotherapy reac-
tion. Five patients in the synchronous arm had severe acute skin
desquamation which required hospitalisation. Four out of the fiveonous versus sequential chemo-radiotherapy in patients with early stage
logy, https://doi.org/10.1016/j.radonc.2019.10.014
Fig. 4. Kaplan–Meier ten-year analyses of secondary outcome measures. Panel A
shows disease free survival defined as the time from randomisation to the earliest
documentation of any recurrence or death. Panel B shows overall survival defined
as the time from randomisation to death from any cause. Patients were censored at
date last seen. The adjusted hazard ratios, 95% confidence intervals and p-values
were derived from Cox regression models. CI = Confidence Interval.
Table 5
Acute and late radiotherapy toxicities.
Synchronous Sequential
N = 1150 N = 1146
Acute Toxicity, n (%) P-value
In-field skin toxicity <0.001*
None 262 (22.9) 410 (36.5)
Mild 599 (52.4) 544 (48.4)
Moderate 231 (20.2) 154 (13.7)
Severe 44 (3.8) 12 (1.1)
Unknown 8 (0.7) 3 (0.3)
Pneumonitis (Acute) 5 (0.4) 1 (0.1) 0.11
Late Toxicity, n (%)
Moderate/severe lymphedema 78 (6.8) 65 (5.7) 0.27
Severe subcutaneous fibrosis 17 (1.5) 11 (1.0) 0.26
Moderate/severe telangiectasia 35 (3.0) 19 (1.7) 0.03
Ischaemic heart disease 7 (0.6) 3 (0.3) 0.28
Rib fracture 7 (0.6) 5 (0.4) 0.50
Symptomatic lung fibrosis 5 (0.4) 3 (0.3) 0.69
Pneumonitis 1 (0.1) 1 (0.1) 1
Brachial plexopathy 2 (0.2) 2 (0.2) 1
P values were calculated by the Chi-squared test. *P-value for in-field skin toxicity
compares patients with moderate/severe toxicity versus none/mild across both
treatments. P-value for late toxicities compares patients with moderate/severe
versus none/mild and also those patients who have or have not experienced a
specific toxicity across both treatment arms.
8 SECRAB: A randomised, phase III, chemo-radiotherapy sequencing breast cancer trialmade a complete recovery with full healing. Three of these patients
had been treated with a >3 weeks radiotherapy schedule. One
patient (two SAEs) developed a chronic ulcer in the inframammary
fold which required surgical intervention. This patient had a signif-
icant breast overhang.
Discussion
This is the largest trial to date reporting the role of adjuvant
synchronous chemo-radiotherapy in the management of breast
cancer. Ten-year follow up concludes that synchronous chemo-
radiotherapy significantly improves local recurrence rates with a
38% reduction in risk of local recurrence (HR 0.62; 95% CI: 0.43–
0.90; p = 0.012). This was delivered with an acceptable modest
increase in acute toxicity. A trend towards benefit of synchronous
chemo-radiotherapy can be seen throughout all subgroups (Fig. 3),
with some groups appearing to receive a greater treatment benefit.
We note that a lack of statistical power is inherent in such analy-
ses. Furthermore we acknowledge that no formal measure has
been taken to address the issue of multiple testing. We also reiter-
ate that the analysis of the anthracycline-CMF chemotherapy ques-
tion was planned and appropriately powered.Please cite this article as: I. N. Fernando, S. J. Bowden, K. Herring et al., Synchr
breast cancer (SECRAB): A randomised, phase III, trial, Radiotherapy and OncoAvoiding local recurrence has enormous psychological and
physical benefits for the patient including avoiding the need to
undergo further surgery. The observed reduction in risk of local
and loco-regional recurrence is particularly pertinent as the results
of the 2011 Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG) overview showed that one life could be saved for every
four recurrences prevented for patients treated by conservative
surgery and radiotherapy [19]. Furthermore, during the 2014
EBCTCG overview, it was also demonstrated that for patients trea-
ted by mastectomy the benefit might be even larger for those with
one-to-three involved lymph nodes where they suggested one
breast cancer death was avoided for every 1.5 recurrences of any
type [23]. We do however note this cannot be generalised to all
node-positive patients especially in those patients with more than
four positive lymph nodes [24] supporting the data presented in
Fig. 3.
The SECRAB trial was not powered for a survival outcome. How-
ever we note a non-significant 4.2% advantage in disease free sur-
vival and a 3.5% advantage in overall survival were seen in the
synchronous arm for patients treated with anthracycline-CMF.
These improvements are consistent with the results of the EBCTCG
overviews [19,23].
The greatest benefit of synchronous chemo-radiation was in
patients treated with anthracycline-CMF even though these
patients would have had a greater delay in starting radiotherapy
compared to those patients treated with CMF. This was a surprising
result as radiotherapy was administered earlier in the synchronous
arm with CMF compared to anthracycline-CMF. It is the delivery of
concurrent treatment which is of paramount importance. In fact
anthracycline-based chemotherapy would now be considered
standard treatment for patients with early breast cancer. The local
recurrence rates, in keeping with many recently reported trials
[25], were lower than originally expected, but for high risk patients
with nodal involvement or ER negative tumours there would be a
substantial benefit [26].
There was an increase in acute skin toxicity, telangiectasia and
myelosuppression in patients treated with synchronous treatment,
but other late effects including pneumonitis, fibrosis, rib fracture,
lymphedema, brachial plexopathy, and cardiac events were similar
in both trial arms. We note that a large cohort such as ours canonous versus sequential chemo-radiotherapy in patients with early stage
logy, https://doi.org/10.1016/j.radonc.2019.10.014
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moderate or severe acute skin reactions had been treated with
radiotherapy schedules >3 weeks and no significant difference in
telangiectasia was seen in those patients treated using a three-
weekly schedule. These data are consistent with the results of
the START trial [27]. It is therefore recommended that synchronous
chemo-radiotherapy should not be used in patients with large
breast size where concerns may be present with regard to acute
skin toxicity [14]. Although we note, with modern forward planned
intensity modulated radiotherapy (IMRT), patients with larger
breast size would have more conformal treatment and less acute
skin toxicity. We would also advise that patients being treated
with synchronous chemo-radiotherapy should be treated with a
three-weekly radiotherapy regimen to avoid additional acute skin
toxicity. Apart from the significant improvement in local/loco-
regional control rates, a further advantage of synchronous treat-
ment is that it shortens the overall treatment time for the patient
as they would complete adjuvant treatment at the end of their last
chemotherapy cycle as opposed to waiting to start radiation fol-
lowing chemotherapy as is standard practice.
The SECRAB trial results are primarily applicable to CMF and
anthracycline–CMF containing regimes which were the standard
UK chemotherapy regimens between 1998 and 2004. However,
the use of taxane (T) chemotherapy schedules are now common
place in early breast cancer. These schedules are problematic in
terms of synchronous radiotherapy administration due to the risk
of acute pulmonary toxicity [28], although it should be noted that
the TACT trial showed no significance difference in disease free
survival between epirubicin-CMF and FEC-T arms [25]. It will
therefore be pertinent to evaluate alternative regimens such as,
E-T-CMF which has been shown to have an improved disease free
survival compared to anthracycline-CMF [29]. They would still
have the advantage that synchronous chemo-radiotherapy could
be used as part of the treatment protocol as it can be given during
the CMF part of the regimen. In addition, these findings may be
translatable to other hypofractionated schedules [30]. For example,
SECRAB may be compatible with dose dense chemotherapy which
has been shown to produce a survival advantage over conventional
chemotherapy particularly in the ER negative patients [31]. Some
of these regimens include CMF such as used by Baldini et al., and
Kummel et al. [32,33]. Finally, it is worth noting that the radiother-
apy techniques used in this trial predate computed tomography
planning, image modulated radiotherapy and other techniques
such as breath-hold which can reduce skin, lung and cardiac toxi-
city, respectively. It may be pertinent to re-evaluate the role of syn-
chronous chemo-radiotherapy using these advanced technologies
with more standard chemotherapy schedules in further ran-
domised studies.
In summary, the results of this study suggest that for any
patient having anthracycline-CMF, radiotherapy should be given
synchronously between the first and second cycle of CMF using a
three week fractionation unless the patient has an excessively
large breast size.Contributors
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